Table of Contents Author Guidelines Submit a Manuscript
Letter to the Editor
Clinical Study
Journal of Immunology Research
Volume 2018, Article ID 5047067, 3 pages
Letter to the Editor

Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”

1Pfizer Biotech, Dublin, Ireland
2Pfizer Biotech, Andover, MA, USA

Correspondence should be addressed to Brian Hassett; moc.rezifp@ttessah.nairb

Received 13 October 2016; Accepted 12 October 2017; Published 30 January 2018

Academic Editor: Ethan M. Shevach

Copyright © 2018 Brian Hassett et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. P. Miranda-Hernández, C. A. López-Morales, F. C. Perdomo-Abúndez et al., “New alternatives for autoimmune disease treatments: physicochemical and clinical comparability of biosimilar etanercept,” Journal of Immunology Research, vol. 2016, Article ID 9697080, 9 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Scheinberg, G. Castaneda Hernandez, M. Li et al., “Variability of intended copies for etanercept in five countries,” Annals of the Rheumatic Diseases, vol. 75, pp. 224-225, 2016, abstract THU0124. View at Publisher · View at Google Scholar
  3. Sandoz, “Arthritis Advisory Committee Briefing Document GP2015 (Proposed INN: etanercept) Biosimilar, June 6th, 2016,” August 2016,
  4. B. Hassett, E. Singh, E. Mahgoub, J. O’Brien, S. Vicik, and B. Fitzpatrick, “Manufacturing history of Enbrel: description of changes to impact overall safety profile and process performance,” Journal of Clinical Rheumatology, vol. 22, p. 158, 2016. View at Google Scholar